Email Updates

Search form

You are here

HIV Vaccine

There is momentum and promise in the search for an HIV vaccine.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available—and an HIV vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. Researchers are expanding on the result of a 2009 trial that showed, for the first time, that a vaccine can reduce the risk of HIV infection. They’re also pursuing groundbreaking research with other novel vaccine strategies, including broadly neutralizing antibodies that target a wide range of HIV strains. At the same time, there is also exciting work in efforts to understand if and how to cure HIV in people who are already infected. The timeline for this work is long and uncertain. Here, too, advocacy is needed to sustain momentum.

Today’s momentum depends on sustained funding. Policy makers and funders around the world must have the courage to sustain vital HIV vaccine research for years to come, and advocates must keep the pressure on them to maintain their commitments.

What We're Reading

POZ magazine takes a look at the benefits that accrue from a vaccine, even one that only cuts the risk of acquiring HIV by half. With the first major trial in seven years underway (HVTN 702), this story speculates on how its success, even if only 50 percent effective, would impact HIV rates when coupled with the full range of prevention strategies.

May 9, 2017
POZ

The opinion page of the New York Times is taking on the anti-vaccine movement. The article challenges those who care about public health to pressure Trump not to empower anti-science sentiments and applauds a bipartisan group of lawmakers who have issued a letter declaring their support for vaccines and the lives they save.

February 23, 2017
The New York Times
Subscribe to RSS - HIV Vaccine